Ulcerative Colitis

01/01/2007 - "* In a well designed phase III trial in patients with active, mild to moderate ulcerative colitis (n = 262), significantly (p < 0.01) more MMX mesalazine 2.4 (34%) or 4.8 g/day (29%) recipients than placebo recipients (13%) achieved clinical and endoscopic remission after 8 weeks of treatment.* In a second phase III trial (n = 341), clinical and endoscopic remission rates with MMX mesalazine 2.4 (40.5%) and 4.8 g/day (41.2%) were significantly (p < 0.01) greater than with placebo (22.1%) after 8 weeks, while the remission rate with non-MMX delayed-release mesalazine (Asacol) [32.6%] did not differ from placebo.* Overall, MMX mesalazine was generally well tolerated in controlled clinical trials, with a similar incidence of treatment-emergent adverse events in placebo (66%) and MMX mesalazine (56%) recipients in a pooled analysis; most adverse events were of mild or moderate severity. "
01/01/2022 - "Mesalazine is the most widely used aminosalicylate for induction and maintenance of remission in patients with mild-to-moderate ulcerative colitis (UC). "
02/01/2011 - "Mesalazine 3.0 g once daily was the most effective dose for maintenance of remission in ulcerative colitis of the three regimens assessed, with no penalty in terms of safety."
09/21/2009 - "5-Aminosalicylic acid (5-ASA) compounds are a highly effective treatment for ulcerative colitis (UC). "
07/01/2007 - "5-Aminosalicylate (5-ASA; mesalamine) is the current first-line treatment for mild to moderate ulcerative colitis, a chronic inflammatory condition that most commonly affects the distal part of the colon. "

01/01/2022 - "Background: Infliximab (IFX) is a potent therapeutic agent used for the treatment of conventional refractory ulcerative colitis (UC). "
02/01/2017 - "Long-term efficacy of infliximab treatment in chronic active ulcerative colitis is excellent especially in patients who respond to induction treatment. "
09/20/2009 - "Besides, infliximab is potent in the remission and its sustaining in ulcerative colitis. "
06/01/2006 - "[Infliximab in active ulcerative colitis -- proven efficacy as induction and maintenance treatment]."
08/01/2001 - "Infliximab appears to be a potent agent for inducing remission in refractory patients with ulcerative colitis."

10/01/2022 - "To carry out better research about the best treatment options and to improve clinical practice in the future, this study aimed to find out how adults with steroid-resistant ulcerative colitis are managed in hospital and why patients and health-care professionals prefer different treatments. "
01/01/2021 - "Acute severe ulcerative colitis (ASUC) is a potentially life-threatening disease, and the best option in cases of steroid-refractory disease is still debated. "
09/28/2008 - "Although systemic steroids are highly efficacious in ulcerative colitis (UC), failure to respond to steroids still poses an important challenge to the surgeon and physician alike. "
09/01/2008 - "In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients."
10/01/2010 - "Ulcerative colitis came to complete remission with short-term steroid monotherapy. "

09/01/2008 - "The introduction of corticosteroids in the 1950s dramatically improved the prognosis of patients with severe ulcerative colitis. "
03/18/2023 - "Corticosteroid-free remission is an important treatment goal for patients with ulcerative colitis [UC]. "
01/01/2020 - "Corticosteroid-free clinical remission is important in ulcerative colitis. "
11/01/2014 - "In patients with more extensive ulcerative colitis, treatment occurs in a step-up fashion (5-ASA, corticosteroids, thiopurines, anti-TNF-α agents), a strategy which has proven effective. "
09/28/2008 - "Corticosteroids are still the first-line treatment for active ulcerative colitis more than 50 years after the publication of trials assessing their beneficial effect, with about a 50% remission rate in cases of severe disease. "

03/01/2014 - "Vedolizumab, an α4β7 antibody, has completed phase 3 trials with very positive results especially for ulcerative colitis. "
02/01/2015 - "In phase III clinical trials, patients with ulcerative colitis had significantly higher rates of clinical response and clinical remission when treated with vedolizumab than when receiving placebo at both 6 and 52 weeks. "
08/08/2014 - "Moderate to high quality data from four studies shows that vedolizumab is superior to placebo for induction of clinical remission and response and endoscopic remission in patients with moderate to severely active ulcerative colitis and prevention of relapse in patients with quiescent ulcerative colitis. "
01/01/2023 - "Vedolizumab showed good safety and effectiveness at inducing remission in children with IBD at 14 weeks, especially those with ulcerative colitis. "
08/08/2014 - "Moderate quality data from one study suggests that vedolizumab is superior to placebo for prevention of relapse in patients with quiescent ulcerative colitis. "

09/01/1990 - "Since the development of sulfasalazine about a half century ago, the prognosis for patients with ulcerative colitis has improved significantly. "
04/01/1985 - "In the case of sulphasalazine, adult slow acetylators require a lower daily dose of the drug than fast acetylators in order to maintain ulcerative colitis in remission without significant side effects. "
06/10/1978 - "Maintenance of remission in ulcerative colitis with sulphasalazine or a high-fibre diet: a clinical trial."
08/01/1985 - "The disparity of the therapeutic efficacy and effects on NK activity of sulphasalazine and its derivatives in vitro may suggest that NK activity is not a major pathogenic mechanism in ulcerative colitis. "
05/01/1983 - "Sulfasalazine is of major benefit in preventing relapses in patients with ulcerative colitis in remission. "

12/01/2022 - "A high adalimumab induction dosing regimen achieves clinical and endoscopic remission in super-refractory ulcerative colitis."
01/01/2022 - "SERENE UC (Study of a Novel Approach to Induction and Maintenance Dosing With Adalimumab in Patients With Moderate to Severe Ulcerative Colitis) evaluated the efficacy of higher adalimumab induction and maintenance dose regimens in patients with ulcerative colitis. "
01/01/2013 - "Adalimumab treatment was associated with a positive benefit/risk balance in the overall population of patients with moderately-to-severely active ulcerative colitis in ULTRA 2; early response was predictive of a positive outcome at 1 year (NCT00408629)."
12/01/2011 - "More recently, data has been published demonstrating the efficacy of adalimumab in patients with ulcerative colitis."
12/01/2017 - "Adalimumab was effective in the treatment of moderate-to-severe ulcerative colitis. "

10/01/2003 - "Cyclosporine A is highly effective in severe attacks of ulcerative colitis (UC) but is associated with important adverse effects that are mainly dose dependent. "
12/01/2020 - "Cyclosporine treatment leads to rapid improvement in severe ulcerative colitis. "
09/04/1998 - "Our data confirm the efficacy of intravenous cyclosporine as a rapid acting drug for severe ulcerative colitis. "
01/25/2005 - "There is limited evidence that cyclosporine is more effective than standard treatment alone for severe ulcerative colitis. "
10/01/2009 - "Although cyclosporin A has been reported to be effective in the treatment of severe ulcerative colitis, factors predicting its therapeutic efficacy remain unclear. "

01/01/2002 - "The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis."
07/04/1992 - "Azathioprine maintenance treatment in ulcerative colitis is beneficial for at least two years if patients have achieved remission while taking the drug. "
05/22/2004 - "To know whether the therapeutic protocol applied in the case of severe acute ulcerative colitis (UC) associating ciclosporine and azathioprine was also effective in the case of moderate chronic active ulcerative colitis (UC). "
01/01/2003 - "Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis."
02/01/2015 - "Azathioprine (AZA) is an established treatment for ulcerative colitis (UC).However, controversy exists regarding its efficacy in inducing and maintaining clinical remission, and long-term data are lacking. "

03/01/2019 - "In our study, we investigated the therapeutic efficacy of RPD and potential mechanism involved in inhibiting dextran sulfate sodium (DSS)-induced ulcerative colitis in mice. "
05/26/2015 - "In our study, we used current biomedical approaches to investigate the therapeutic efficacy of BXD and possible protective mechanism involved in inhibiting dextran sulfate sodium (DSS)-induced chronic ulcerative colitis model. "
08/30/2022 - "The purpose of this study is to investigate the protective effects and potential mechanisms of ZO extracted from ginger on dextran sulfate sodium (DSS)-induced mouse ulcerative colitis (UC). "
01/01/2012 - "The aim of this study was to investigate the protective effects of CA against dextran sulfate sodium (DSS)-induced ulcerative colitis (UC). "
07/07/2021 - "In the present investigation, the potential protective effects of whey fermented with probiotic Lactobacillus rhamnosus MTCC-5897 on gastrointestinal health in a murine ulcerative colitis model induced by dextran sulfate sodium (DSS) were evaluated. "

01/01/2023 - "Ulcerative colitis (UC) has become a global epidemic, and the lack of an effective cure highlights the necessity and urgency to explore novel therapies. "
08/01/2015 - "The most important goals of the recent therapies of ulcerative colitis (UC) are to induce and maintain clinical remission and to achieve mucosal healing (MH). "
09/01/1997 - "The optimal dosage of oral 5-ASA in the maintenance therapy of ulcerative colitis in remission is not clear. "
10/15/1994 - "The results may suggest that substitution therapy with F XIII concentrate can be beneficial in patients with therapy-resistant active stage of ulcerative colitis and proven F XIII deficiency. "
09/19/2023 - "This study is aimed at assessing the potential of liposomal formulations of TQ and Egyptian PP in combination therapy on improving their therapeutic efficacy against ulcerative colitis in order to maximize the potential of their beneficial clinical effects. "

04/20/1993 - "5-ASA enemas are very effective in the treatment of distal ulcerative colitis. "
09/01/2018 - "Thus, POL enema might be considered as a potential effective treatment for ulcerative colitis patients."
09/01/2005 - "To explore the therapeutic efficacy of patients with ulcerative colitis (UC) treated by retention enema and per-colonoscopic spraying of Zhikang Compound Liquid (ZKCL). "
02/01/2004 - "Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis."
01/01/1999 - "SCFAs enemas or oral probiotics are a new and promising treatment for ulcerative colitis. "

03/01/2017 - "Despite advances in therapeutic options, more than half of all patients with ulcerative colitis [UC] do not achieve long-term remission, many require colectomy, and the disease still has a marked negative impact on quality of life. "
04/01/2016 - "A significant reduction of colectomy and mortality rates in severe ulcerative colitis was observed in the last 40 years. "
09/01/2011 - "A significant proportion of patients with ulcerative colitis will still have to undergo colectomy and overall half of the patients do not achieve sustained remission, leading to impairment of physical and mental health, social life, employment issues and sexual activity. "
09/01/2006 - "Our findings may help to predict patients with ulcerative colitis who have a high risk for colectomy."
01/01/2020 - "Currently, the treatment goal in ulcerative colitis (UC) is to achieve clinical and endoscopic remission; nevertheless, histologic remission is a potential new treatment goal since it is associated with favorable long-term clinical outcome lower rates of hospitalization, complications, and colectomies. "

10/01/2015 - "Ileal pouch-anal anastomosis has long-term durability as a cure for pediatric chronic ulcerative colitis, with most patients reporting stable bowel function and QoL. "
10/01/2010 - "There are clearly significant adverse affects on health-related quality of life in children with ulcerative colitis that dramatically improved following restorative proctocolectomy."
06/01/2001 - "Restorative proctocolectomy has dramatically improved the treatment of familial polyposis and ulcerative colitis with rectal involvement. "
02/01/1995 - "Total proctocolectomy and ileal pouch-anal anastomosis (IPAA) is the best option in the surgical treatment of ulcerative colitis, and for some patients with familial polyposis. "
01/01/2022 - "Management of ulcerative colitis after surgery suggested by guidelines (total proctocolectomy with ileal-pouch anal anastomosis) is a big challenge for physicians because patients who believed that their disease had been cured started experiencing very uncomfortable symptoms repeatedly. "

12/01/2009 - "An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment."
12/07/2014 - "Granulo-monocyto apheresis is more effective in mild ulcerative colitis than in moderate to severe disease."
02/01/2017 - "Granulocyte and monocyte apheresis (GMA) has shown therapeutic efficacy in active ulcerative colitis (UC). "
05/07/2016 - "Adacolumn(®) GMA apheresis treatment was effective in pediatric patients with moderate active Ulcerative Colitis. "
02/01/2009 - "Leukocytapheresis is effective for ulcerative colitis (UC), and both peripheral leukocyte and platelet counts decrease during apheresis. "